Overview

Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL

Status:
Not yet recruiting

Trial end date:
2032-11-01

Target enrollment:

Participant gender:

Summary

In this study, efficacy and safety of 2 regimens that combine the CD3-CD20 T cell engager epcoritamab with venetoclax will be tested in relapsed/refractory CLL and SLL patients. The trial starts with phase I part to establish the recommended dose level (RDL) of epcoritamab in the combination with venetoclax for the phase II trial.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators:

German CLL Study Group
Nordic CLL Study Group

Treatments:

Venetoclax